Chemed Corporation — FY2016 Form 10-K
Business context and reporting period
Annual report for the fiscal year ended December 31, 2016, filed February 27, 2017. Chemed operates two segments: VITAS, a hospice and palliative-care provider, and Roto-Rooter, which provides plumbing, drain-cleaning and water-restoration services.
Financial position and key metrics
- Debt: Long-term debt was $108.8 million at year-end, all at variable interest rates. A 100-basis-point rate change would alter annual interest expense by $100,000 for each $10 million borrowed.
- VITAS payer mix: More than 95% of VITAS revenue came from Medicare and Medicaid; approximately 95% was from Medicare. Medicaid accounted for 5% of VITAS revenue in 2016.
- Legal and environmental costs: Costs related to the U.S. v. VITAS matter and related regulatory issues were $5.3 million in 2016, versus $5.0 million in 2015 and $2.1 million in 2014. Environmental cleanup accruals were $1.7 million; the company also disclosed contingent DuBois-related exposure up to $14.9 million, for which no additional provision was recorded.
- Shareholder returns: Quarterly dividends were $0.24, $0.24, $0.26 and $0.26 per share, totaling $1.00 for 2016, compared with $0.92 in 2015. Chemed repurchased 780,134 shares at a reported weighted-average price of $131.15. At year-end, $50.2 million remained under the repurchase program.
- Other financial results: Revenue, net income, operating margins, cash flow and liquidity figures are not clearly provided in the supplied filing text; the 10-K incorporates the financial statements and MD&A from the separate 2016 Annual Report to Stockholders.
Changes versus the prior comparable period
- Effective January 1, 2016, Medicare hospice routine-home-care reimbursement shifted to a two-tier rate, with a higher rate for a patient’s first 60 days and a lower rate thereafter. A Service Intensity Add-on payment also began for qualifying nurse or social-worker visits in the final seven days of a patient’s life.
- Quarterly dividends increased during 2016; annual per-share dividends were $1.00, compared with $0.92 in 2015.
- Costs associated with the VITAS government case and related regulatory matters rose to $5.3 million from $5.0 million in 2015.
Outlook, risks, contingencies and unusual items
- The filing provides no specific earnings or revenue guidance. Management notes that VITAS profitability depends on managing care costs against government per-diem reimbursement, which may rise more slowly than labor and other expenses.
- VITAS is exposed to Medicare and Medicaid rate, eligibility, cap and audit changes. Medicare hospice payments are subject to payment caps; the filing states the overall cap was $27,820.75 per admission for the year ended October 31, 2016.
- The False Claims Act case alleges improper continuous-home-care billing and hospice eligibility claims. The case was in discovery; Chemed stated it could not reasonably estimate the probability or range of loss. The complaint seeks treble damages and other relief.
- Two California employee class-action lawsuits allege wage-and-hour and related violations. The company likewise could not estimate the probability or range of loss and said it intended to defend the claims. A shareholder derivative case was also ongoing in the disclosed procedural history.
- Other notable risks include labor shortages and wage pressure, particularly for nurses; intense competition; regulatory and reimbursement uncertainty; variable-rate debt; and hurricane exposure in south Florida, where VITAS has its headquarters and major operations.
- Chemed recorded $1.7 million for environmental matters tied to former operations and stated that additional DuBois-related cleanup liability, up to $14.9 million, was not considered probable and therefore was not accrued.
- Management reported no known cyberattacks that compromised customer, patient or company data, but cautioned that safeguards cannot eliminate the risk.
Important facts for investors to verify
- Review the incorporated 2016 Annual Report for audited revenue, earnings, margins, cash flow, balance-sheet liquidity and segment results, which are absent from the supplied text.
- Check subsequent developments, reserves and potential exposure in the VITAS False Claims Act matter and the California employment lawsuits.
- Assess VITAS’s sensitivity to Medicare and Medicaid reimbursement, payment caps, claim audits, patient eligibility scrutiny and operating-cost inflation.
- Confirm debt maturity, credit-facility capacity, covenants and interest-rate exposure using the debt footnotes and credit agreement.
- Track environmental remediation estimates, dividend capacity and remaining authorization under the share-repurchase program.